Ciloxan Ophthalmic Solution for Effective Bacterial Conjunctivitis Treatment
| Product dosage: 5 ml | |||
|---|---|---|---|
| Package (num) | Per flacon | Price | Buy |
| 4 | $10.75 | $43.00 (0%) | 🛒 Add to cart |
| 5 | $9.80 | $53.75 $49.02 (9%) | 🛒 Add to cart |
| 6 | $9.03
Best per flacon | $64.50 $54.18 (16%) | 🛒 Add to cart |
Synonyms | |||
Ciloxan (ciprofloxacin hydrochloride ophthalmic solution) 0.3% is a sterile, antimicrobial topical solution formulated for the treatment of ocular infections caused by susceptible strains of bacteria. As a fluoroquinolone antibiotic, it offers potent bactericidal activity through inhibition of bacterial DNA gyrase and topoisomerase IV. This prescription medication is indicated for corneal ulcers and bacterial conjunctivitis, providing targeted therapy with a well-established efficacy and safety profile. Proper diagnosis by a healthcare professional is essential prior to initiation of treatment.
Features
- Contains 0.3% ciprofloxacin hydrochloride as the active pharmaceutical ingredient
- Sterile, isotonic, buffered solution with pH approximately 4.5–5.5
- Preservative: benzalkonium chloride 0.006%
- Available in 2.5 mL and 5 mL opaque, white LDPE plastic dropper bottles
- Bactericidal activity against a broad spectrum of Gram-positive and Gram-negative ocular pathogens
Benefits
- Rapid bactericidal action eradicates susceptible pathogens at the infection site
- High corneal penetration achieves effective tissue concentrations
- Convenient dosing regimen supports patient adherence to therapy
- Demonstrated clinical efficacy in resolving signs and symptoms of bacterial conjunctivitis
- Low incidence of systemic absorption when used as directed
- Trusted fluoroquinolone with extensive clinical history and microbiological data
Common use
Ciloxan ophthalmic solution is primarily prescribed for the treatment of bacterial conjunctivitis caused by susceptible strains of Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Enterobacter cloacae. It is also indicated for corneal ulcers caused by susceptible strains of Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and certain species of Corynebacterium. The solution may be used as part of a comprehensive ophthalmic management strategy under appropriate medical supervision.
Dosage and direction
For bacterial conjunctivitis: Instill 1–2 drops into the affected eye(s) every 2 hours while awake for the first 2 days, then 1–2 drops every 4 hours while awake for the next 5 days. For corneal ulcers: Instill 2 drops into the affected eye every 15 minutes for the first 6 hours, then 2 drops every 30 minutes for the remainder of the first day. On day 2, instill 2 drops hourly. From day 3 through day 14, instill 2 drops every 4 hours. Treatment may be extended beyond 14 days if corneal re-epithelialization has not occurred. Wash hands before use. Avoid contaminating the dropper tip. Do not touch the eye or any surface with the dropper.
Precautions
Use under medical supervision only. Not for injection or oral use. Patients should not wear contact lenses during treatment. Discontinue use and consult a physician if irritation, rash, or allergic reaction occurs. Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Use with caution in patients with a history of hypersensitivity to quinolones. The safety and effectiveness in pediatric patients below 1 year of age have not been established.
Contraindications
Hypersensitivity to ciprofloxacin, other quinolones, or any component of the formulation. History of tendinitis or tendon rupture associated with quinolone use. Not indicated for viral, fungal, or mycobacterial ocular infections. Should not be used in patients wearing contact lenses due to potential interaction with the preservative benzalkonium chloride.
Possible side effect
Most common: transient ocular burning, discomfort, or itching; blurred vision; foreign body sensation; photophobia; tearing; dryness; ocular precipitation/whitish crystals; corneal staining; conjunctival hyperemia; bad taste following instillation. Less common: eyelid edema, ocular pain, superficial keratitis, ocular itching, corneal infiltrates, nausea, decreased vision. Rare: allergic reactions, lid margin crusting, corneal erosion, corneal ulceration, dizziness, corneal staining, nasal dryness. Systemic reactions are rare but may include hypersensitivity reactions.
Drug interaction
Specific ophthalmic drug interaction studies have not been conducted. Theoretically, concurrent use with other ophthalmic solutions containing cations (e.g., zinc) may reduce efficacy due to chelation. Separate administration of other eye medications by at least 5 minutes. Systemic absorption is minimal, but caution is advised when using with other fluoroquinolones systemically due to potential additive effects.
Missed dose
If a dose is missed, administer as soon as possible. However, if it is almost time for the next dose, skip the missed dose and continue with the regular dosing schedule. Do not double the dose to make up for a missed one. Maintain the prescribed frequency to ensure adequate antibiotic concentrations at the infection site.
Overdose
Ocular overdose is unlikely to cause significant systemic effects due to minimal absorption. If accidentally ingested, gastric lavage and supportive measures may be considered. Ocular irrigation with sterile saline may be performed if excessive installation occurs. No specific antidote exists. Symptomatic treatment should be provided as necessary.
Storage
Store at controlled room temperature 15°–30°C (59°–86°F). Protect from light. Keep bottle tightly closed when not in use. Discard any unused solution 28 days after opening. Do not freeze. Keep out of reach of children. Do not use if solution changes color or becomes cloudy.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment recommendations. The prescribing physician should be aware of the complete medical history of the patient. Full prescribing information should be reviewed before initiation of therapy.
Reviews
“Clinical studies demonstrate Ciloxan’s efficacy in achieving clinical resolution of bacterial conjunctivitis in 85–90% of patients by day 7–10 of treatment. Microbiological eradication rates typically exceed 90% for susceptible organisms. The formulation is generally well-tolerated, with most adverse effects being mild and transient. Ophthalmologists appreciate its reliable spectrum of activity against common ocular pathogens and convenient dosing schedule that promotes patient compliance.”